Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.

Tina Bjørnlund Bønsdorff

Chief Scientific Officer

bonsdorff@oncoinvent.com

+47 470 24 922

Dr. Tina B. Bønsdorff has more than 15 years of research experience in molecular biology. She has a Ph.D. and postdoctoral experience from the Norwegian School of Veterinary Science, where she worked in the field of gene identification, expression and mutation analysis. Her postdoctoral research was focused on gene expression analysis of early neoplastic lesions in dog with inherited cancer syndromes. Dr. Bønsdorff is one of the founders of Oncoinvent AS. Dr. Bønsdorff has been the Chief Scientific Officer of Oncoinvent AS from the start-up, and was the CEO of the company from August 2013 to September 2016.

Kari Myren

Chief Medical Officer

myren@oncoinvent.com

+47 408 58 241

Dr. Kari Myren is a medical professional with a strong clinical background with specialty training in surgery. She has ten years of experience from leading positions in both the pharmaceutical and MedTech industries relating to oncology and early phase immuno-oncology, as well as clinical experience from oncologic surgery.  Dr. Myren has previously held the positions of Medical Advisor and Senior Medical Advisor at Novartis and Roche Diagnostics respectively.  Dr. Myren comes to Oncoinvent from Photocure ASA where she held the position of Vice President Global Medical Affairs and Clinical Development.

Tore Kvam

Chief Financial Officer

kvam@oncoinvent.com

+47 959 34 199

Tore Kvam has an extensive experience as CFO within technology driven companies and with a lifelong experience within financial management and operations, as well as working with investors and owners developing companies. In the later years he has also gained significant experience and knowledge within the life science industry working with clinical phase companies in their efforts to advance their product candidates and attract life science investors. Mr. Kvam holds a MSc Computer Science degree from the George Washington University, an MBA from the Norwegian Business School BI and is a Certified European Financial Analyst (CEFA).

Kristine Lofthus

Head of Quality Assurance

lofthus@oncoinvent.com

+47 932 06 611

Kristine Lofthus has more than 15 years experience with the manufacturing of pharmaceuticals. Her main field of expertise is the manufacturing of aseptic and terminally sterilized injectables, and in particular radiopharmaceuticals. This experience includes production and production management, quality assurance and the certification and release of batches as a Qualified Person. Kristine holds a cand. pharm. degree (M.Sc.) from the University of Oslo, a certificate of Advanced Studies (CAS) in Radiopharmaceutical Chemistry/Radiopharmacy from Eidgenössische Technische Hochschule Zürich and is a licensed Qualified Person at Oncoinvent AS

 

Stian Brekke

Head of Regulatory Affairs

brekke@oncoinvent.com

+47 951 06 031

Mr. Stian Brekke has worked in regulatory affairs since 2005, as a regulatory affairs manager, regulatory project leader and QPPV during 11 years in Pharmaq AS, and since April 2019 as a regulatory affairs director at SMERUD, based in Oslo, Norway.  Mr. Brekke has led multiple regulatory submissions to various competent authorities, including marketing authorisation applications, orphan drug designation applications, variation applications, clinical trial applications etc.  He has ensured regulatory compliance in close collaboration with clinical R&D units, specialized laboratories, consultants, and regulatory authorities as the regulatory representative in drug development projects.

Anne-Kirsti Aksnes

VP of Clinical Operations

Dr. Anne-Kirsti Aksnes is a multi-disciplinary clinical research professional with more than 20 years of experience within clinical research and development in the pharmaceutical and biotech industry.  Dr. Aksnes has a strong knowledge of all aspects of clinical development and operations and a broad and reputable experiences with clinical studies in all phases (I-IV).  She is a physiologist by training with a Medical Doctorate Degree (PhD) from Karolinska Institute in Sweden.  Dr. Aksnes has held multiple senior positions including VP Clinical Development at Targovax ASA and Director of Clinical Research at G.E. Healthcare.  Dr. Aksnes also held the position of VP Clinical Development at Algeta ASA and was responsible for the clinical development of Xofigo, a product that has gone on to become the world’s most successful and largest selling radiopharmaceutical.

 

Hans Hild

Head of Production

hild@oncoinvent.com

+47 971 24 060

Dr. Hans M. Hild has more than 15 years’ experience in the GMP compliant production of sterile- and aseptically produced pharmaceuticals and radiopharmaceuticals. He previously has worked for the Institute for Energy Technology, GE Healthcare, Avecia Biotechnology (formerly Zeneca LSM Ltd.) and Degussa AG, and has a strong background in pharmaceutical process development, scale-up and technology transfer. He has extensive experience in the production of biopharmaceuticals and contrast media for early clinical studies, as well as experience in the commercial production of radiopharmaceuticals. Dr. Hild holds an Dipl. Ing. (FH) degree in Chemical Engineering from FH Frankfurt am Main, an M.Sc. in Biochemical Engineering from the University of Birmingham and a Ph.D. in Biochemical Engineering from Imperial College London.

Gro Hjellum

Head of Quality Control

hjellum@oncoinvent.com

+47 979 83 092

Gro Hjellum has more than 25 years of experience within research & development and operations in the pharmaceutical and biotech industry, ranging from analytical sciences, quality control and bio-analysis from preclinical product development through to regulatory approval of products. Prior to joining Oncoinvent, Gro worked for Nycomed/GE-Healthcare and Algeta/Bayer. She has a strong background in radiopharmaceutical product development and technology transfer to contract manufacturers in Norway as well as to US and Japan. Ms. Hjellum holds an MSc degree in radiochemistry from the University of Oslo.